120 related articles for article (PubMed ID: 7812346)
1. A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1.
Kuzel T; Rosen ST; Zimmer AM; Silverstein EA; Spies S; Saletan SL; Norvitch ME; Birkhofer M; Shochat D; LoBuglio AF
Cancer Biother; 1993; 8(1):3-16. PubMed ID: 7812346
[TBL] [Abstract][Full Text] [Related]
2. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; Lamborn KR; Levy NB; McGahan JP; Salako Q; Shen S; Lewis JP
J Clin Oncol; 1998 Oct; 16(10):3246-56. PubMed ID: 9779698
[TBL] [Abstract][Full Text] [Related]
3. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
Denardo GL; Denardo SJ; Kukis DL; O'Donnell RT; Shen S; Goldstein DS; Kroger LA; Salako Q; Denardo DA; Mirick GR; Mausner LF; Srivastava SC; Meares CF
Anticancer Res; 1998; 18(4B):2779-88. PubMed ID: 9713461
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
5. Milestones in the development of Lym-1 therapy.
DeNardo GL; O'Donnell RT; Rose LM; Mirick GR; Kroger LA; DeNardo SJ
Hybridoma; 1999 Feb; 18(1):1-11. PubMed ID: 10211782
[TBL] [Abstract][Full Text] [Related]
6. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP
J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
O'Donnell RT; Shen S; Denardo SJ; Wun T; Kukis DL; Goldstein DS; Denardo GL
Anticancer Res; 2000; 20(5C):3647-55. PubMed ID: 11268433
[TBL] [Abstract][Full Text] [Related]
8. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.
DeNardo GL; DeNardo SJ; Lamborn KR; Goldstein DS; Levy NB; Lewis JP; O'Grady LF; Raventos A; Kroger LA; Macey DJ; McGahan JP; Mills SL; Shen S
Cancer Biother Radiopharm; 1998 Aug; 13(4):239-54. PubMed ID: 10850360
[TBL] [Abstract][Full Text] [Related]
9. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S
Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma.
Czuczman MS; Straus DJ; Divgi CR; Graham M; Garin-Chesa P; Finn R; Myers J; Old LJ; Larson SM; Scheinberg DA
J Clin Oncol; 1993 Oct; 11(10):2021-9. PubMed ID: 8410126
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.
Divgi CR; Bander NH; Scott AM; O'Donoghue JA; Sgouros G; Welt S; Finn RD; Morrissey F; Capitelli P; Williams JM; Deland D; Nakhre A; Oosterwijk E; Gulec S; Graham MC; Larson SM; Old LJ
Clin Cancer Res; 1998 Nov; 4(11):2729-39. PubMed ID: 9829736
[TBL] [Abstract][Full Text] [Related]
13. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.
Kaminski MS; Zasadny KR; Francis IR; Fenner MC; Ross CW; Milik AW; Estes J; Tuck M; Regan D; Fisher S; Glenn SD; Wahl RL
J Clin Oncol; 1996 Jul; 14(7):1974-81. PubMed ID: 8683227
[TBL] [Abstract][Full Text] [Related]
14. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression.
Scheinberg DA; Straus DJ; Yeh SD; Divgi C; Garin-Chesa P; Graham M; Pentlow K; Coit D; Oettgen HF; Old LJ
J Clin Oncol; 1990 May; 8(5):792-803. PubMed ID: 2332769
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
Leahy MF; Seymour JF; Hicks RJ; Turner JH
J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
Kaminski MS; Zasadny KR; Francis IR; Milik AW; Ross CW; Moon SD; Crawford SM; Burgess JM; Petry NA; Butchko GM
N Engl J Med; 1993 Aug; 329(7):459-65. PubMed ID: 7687326
[TBL] [Abstract][Full Text] [Related]
17. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer.
Murray JL; Macey DJ; Kasi LP; Rieger P; Cunningham J; Bhadkamkar V; Zhang HZ; Schlom J; Rosenblum MG; Podoloff DA
Cancer; 1994 Feb; 73(3 Suppl):1057-66. PubMed ID: 8306248
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
Chong G; Lee FT; Hopkins W; Tebbutt N; Cebon JS; Mountain AJ; Chappell B; Papenfuss A; Schleyer P; U P; Murphy R; Wirth V; Smyth FE; Potasz N; Poon A; Davis ID; Saunder T; O'keefe GJ; Burgess AW; Hoffman EW; Old LJ; Scott AM
Clin Cancer Res; 2005 Jul; 11(13):4818-26. PubMed ID: 16000579
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
20. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.
Goldenberg DM; Horowitz JA; Sharkey RM; Hall TC; Murthy S; Goldenberg H; Lee RE; Stein R; Siegel JA; Izon DO
J Clin Oncol; 1991 Apr; 9(4):548-64. PubMed ID: 2066752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]